These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 26589238)
101. [Use of oral glucose-lowering agents in patients with renal impairment]. Scheen AJ; Paquot N Rev Med Liege; 2017 Oct; 72(10):462-468. PubMed ID: 29058840 [TBL] [Abstract][Full Text] [Related]
102. Effectiveness and safety of new oral and injectable agents for in-hospital management of type 2 diabetes in general wards: Systematic review and meta-analysis. Soto-Chávez MJ; Muñoz-Velandia OM; Alzate-Granados JP; Lombo CE; Henao-Carrillo DC; Gómez-Medina AM Diabetes Res Clin Pract; 2022 Sep; 191():110019. PubMed ID: 35931222 [TBL] [Abstract][Full Text] [Related]
103. Sodium glucose cotransporter-2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function. Chan YH; Hsu TJ; Wang CL; Kao YW; Huang CY; Chu PH ESC Heart Fail; 2020 Oct; 7(5):2784-2796. PubMed ID: 32627380 [TBL] [Abstract][Full Text] [Related]
104. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Bonora BM; Avogaro A; Fadini GP Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913 [TBL] [Abstract][Full Text] [Related]
105. [New antidiabetic drugs: current status and future prospects - a review of the literature]. Baranowska A; Stefanowicz-Rutkowska M; Matuszewski W; Bandurska-Stankiewicz E Wiad Lek; 2018; 71(8):1588-1598. PubMed ID: 30684345 [TBL] [Abstract][Full Text] [Related]
106. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease. Kornelius E; Huang CN; Lo SC; Wang YH; Yang YS Endocr Pract; 2020 Dec; 26(12):1486-1496. PubMed ID: 33471741 [TBL] [Abstract][Full Text] [Related]
107. Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor. Kusunoki M; Sato D; Sakazaki T; Miyata T; Tsutsumi K; Oshida Y Drug Res (Stuttg); 2020 Apr; 70(4):131-136. PubMed ID: 32164029 [TBL] [Abstract][Full Text] [Related]
108. How attractive is the combination of a sodium glucose co-transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes? Schernthaner G; Schernthaner-Reiter MH Diabetes Obes Metab; 2015 Jul; 17(7):613-5. PubMed ID: 26018554 [No Abstract] [Full Text] [Related]
110. The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Kobayashi K; Toyoda M; Hatori N; Sato K; Miyakawa M; Tamura K; Kanamori A J Diabetes Res; 2021; 2021():6573369. PubMed ID: 35028319 [TBL] [Abstract][Full Text] [Related]
112. Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong. Lui DTW; Wu T; Tang EHM; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH Diabetes Res Clin Pract; 2023 Mar; 197():110576. PubMed ID: 36780955 [TBL] [Abstract][Full Text] [Related]
114. Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia. Boucaud-Maitre D BMJ; 2016 Jun; 353():i3186. PubMed ID: 27267596 [No Abstract] [Full Text] [Related]
115. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study. Chung YR; Ha KH; Lee K; Kim DJ PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289 [TBL] [Abstract][Full Text] [Related]
116. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. McGovern AP; Hogg M; Shields BM; Sattar NA; Holman RR; Pearson ER; Hattersley AT; Jones AG; Dennis JM; BMJ Open Diabetes Res Care; 2020 May; 8(1):. PubMed ID: 32448787 [TBL] [Abstract][Full Text] [Related]
117. New therapies for diabesity. Bailey CJ Curr Diab Rep; 2009 Oct; 9(5):360-7. PubMed ID: 19793506 [TBL] [Abstract][Full Text] [Related]
119. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study. Seong JM; Yee J; Gwak HS Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554 [TBL] [Abstract][Full Text] [Related]
120. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Yabe D; Nishikino R; Kaneko M; Iwasaki M; Seino Y Expert Opin Drug Saf; 2015 Jun; 14(6):795-800. PubMed ID: 25851664 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]